Search

Your search keyword '"De bari, B."' showing total 501 results
Start Over Author "De bari, B."
501 results on '"De bari, B."'

2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

4. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

Author

Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, and Franco P

Subjects
NLR, PLR, SII, Anal cancer, prognostic factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Andrea Casadei-Gardini,1 Francesco Montagnani,2 Chiara Casadei,1 Francesca Arcadipane,3 Kalliopi Andrikou,4 Deborah Aloi,5 Alessandra Anna Prete,6,7 Maria Giulia Zampino,8 Antonella Argentiero,9 Giuseppe Pugliese,4 Stefania Martini,10 Giuseppe Carlo Iorio,10 Mario Scartozzi,11 Massimiliano Mistrangelo,12 Lorenzo Fornaro,13 Paola Cassoni,14 Giorgia Marisi,15 Veronica Dell’Acqua,16 Paola Simona Ravenda,8 Sara Lonardi,6 Nicola Silvestris,7 Berardino De Bari,5 Umberto Ricardi,3 Stefano Cascinu,4 Pierfrancesco Franco91Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 2Oncology Department, SOC Oncology, ASL (Health Local Authority), Biella, Italy; 3Department of Oncology, Radiation Oncology, AOU Città della Salute e della Scienza, Turin, Italy; 4Department of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy; 5Radiation Oncology Department, Centre Hospitalier Régional Universitaire “Jean Minjoz”, Besançon Cedex, France; 6Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy; 7Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I University Hospital, Rome, Italy; 8Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy; 9Medical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy; 10Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy; 11Department of Medical Oncology, University of Cagliari, Cagliari, Italy; 12Department of Surgical Sciences, University of Turin, Turin, Italy; 13Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana University, Pisa, Italy; 14Department of Medical Sciences, Pathology Unit, University of Turin, Turin, Italy; 15Biosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy; 16Department of Radiotherapy, IRCCS, European Institute of Oncology, Milan, ItalyBackground: In anal cancer, there are no markers nor other laboratory indexes that can predict prognosis and guide clinical practice for patients treated with concurrent chemoradiation. In this study, we retrospectively investigated the influence of immune inflammation indicators on treatment outcome of anal cancer patients undergoing concurrent chemoradiotherapy.Methods: All patients had a histologically proven diagnosis of squamous cell carcinoma of the anal canal/margin treated with chemoradiotherapy according to the Nigro’s regimen. Impact on prognosis of pre-treatment systemic index of inflammation (SII) (platelet x neutrophil/lymphocyte), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were analyzed.Results: A total of 161 consecutive patients were available for the analysis. Response to treatment was the single most important factor for progression-free survival (PFS) and overall survival (OS). At univariate analysis, higher SII level was significantly correlated to lower PFS (p

Published
2019

6. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Author

Salas, S., Resseguier, N., Blay, J.Y., Le Cesne, A., Italiano, A., Chevreau, C., Rosset, P., Isambert, N., Soulie, P., Cupissol, D., Delcambre, C., Bay, J.O., Dubray-Longeras, P., Krengli, M., De Bari, B., Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Duffaud, F., Penel, N., Bertucci, F., Ranchere-Vince, D., Terrier, P., Bonvalot, S., Macagno, N., Lemoine, C., Lae, M., Coindre, J.M., and Bouvier, C.

Published
2017
Full Text
View/download PDF

9. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

Author

Nicosia, L, Franceschini, D, Perrone-Congedi, F, Casamassima, F, Gerardi, M, Rigo, M, Mazzola, R, Perna, M, Scotti, V, Fodor, A, Iurato, A, Pasqualetti, F, Gadducci, G, Chiesa, S, Niespolo, R, Bruni, A, Alicino, G, Frassinelli, L, Borghetti, P, Di Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Lunardi, G, Valdagni, R, Fazio, I, Scarzello, G, Corti, L, Vavassori, V, Maranzano, E, Magrini, S, Arcangeli, S, Gambacorta, M, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, Alongi, F, Nicosia L., Franceschini D., Perrone-Congedi F., Casamassima F., Gerardi M. A., Rigo M., Mazzola R., Perna M., Scotti V., Fodor A., Iurato A., Pasqualetti F., Gadducci G., Chiesa S., Niespolo R. M., Bruni A., Alicino G., Frassinelli L., Borghetti P., Di Marzo A., Ravasio A., De Bari B., Sepulcri M., Aiello D., Mortellaro G., Sangalli C., Franceschini M., Montesi G., Aquilanti F. M., Lunardi G., Valdagni R., Fazio I., Scarzello G., Corti L., Vavassori V., Maranzano E., Magrini S. M., Arcangeli S., Gambacorta M. A., Valentini V., Paiar F., Ramella S., Di Muzio N. G., Livi L., Jereczek-Fossa B. A., Osti M. F., Scorsetti M., Alongi F., Nicosia, L, Franceschini, D, Perrone-Congedi, F, Casamassima, F, Gerardi, M, Rigo, M, Mazzola, R, Perna, M, Scotti, V, Fodor, A, Iurato, A, Pasqualetti, F, Gadducci, G, Chiesa, S, Niespolo, R, Bruni, A, Alicino, G, Frassinelli, L, Borghetti, P, Di Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Lunardi, G, Valdagni, R, Fazio, I, Scarzello, G, Corti, L, Vavassori, V, Maranzano, E, Magrini, S, Arcangeli, S, Gambacorta, M, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, Alongi, F, Nicosia L., Franceschini D., Perrone-Congedi F., Casamassima F., Gerardi M. A., Rigo M., Mazzola R., Perna M., Scotti V., Fodor A., Iurato A., Pasqualetti F., Gadducci G., Chiesa S., Niespolo R. M., Bruni A., Alicino G., Frassinelli L., Borghetti P., Di Marzo A., Ravasio A., De Bari B., Sepulcri M., Aiello D., Mortellaro G., Sangalli C., Franceschini M., Montesi G., Aquilanti F. M., Lunardi G., Valdagni R., Fazio I., Scarzello G., Corti L., Vavassori V., Maranzano E., Magrini S. M., Arcangeli S., Gambacorta M. A., Valentini V., Paiar F., Ramella S., Di Muzio N. G., Livi L., Jereczek-Fossa B. A., Osti M. F., Scorsetti M., and Alongi F.

Abstract

Introduction: Stereotactic ablative radiotherapy (SABR) has been shown to increase survival in oligometastatic disease, but local control of colorectal metastases remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate the progression to the polymetastatic disease (PMD). Material and methods: The study involved 23 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1033 lung metastases were reported. Clinical and biological parameters were evaluated as predictive for freedom from local progression-free survival (FLP). Secondary end-point was the time to the polymetastatic conversion (tPMC). Results: Two-year FLP was 75.4%. Two-year FLP for lesions treated with a BED < 00 Gy, 100–124 Gy, and ≥125 Gy was 76.1%, 70.6%, and 94% (p = 0.000). Two-year FLP for lesion measuring ≤10 mm, 10–20 mm, and >20 mm was 79.7%, 77.1%, and 66.6% (p = 0.027). At the multivariate analysis a BED ≥125 Gy significantly reduced the risk of local progression (HR 0.24, 95%CI 0.11–0.51; p = 0.000). Median tPMC was 26.8 months. Lesions treated with BED ≥125 Gy reported a significantly longer tPMC as compared to lower BED. The median tPMC for patients treated to 1, 2–3 or 4–5 simultaneous oligometastases was 28.5, 25.4, and 9.8 months (p = 0.035). Conclusion: The present is the largest series of lung colorectal metastases treated with SABR. The results support the use of SBRT in lung oligometastatic colorectal cancer patients as it might delay the transition to PMD or offer relatively long disease-free period in selected cases. Predictive factors were identified for treatment personalization.

Published
2022

11. OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations

Author

Kroeze, S., primary, Pavic, M., additional, Stellamans, K., additional, Lievens, Y., additional, Becherini, C., additional, Scorsetti, M., additional, Alongi, F., additional, Ricardi, U., additional, Jereczek, B., additional, Westhoff, P., additional, But-Hadzic, J., additional, Widder, J., additional, Geets, X., additional, Bral, S., additional, Lambrecht, M., additional, Billiet, C., additional, Sirak, I., additional, Ramella, S., additional, Battista, I.G., additional, Benavente, S., additional, Zapatero, A., additional, Romero, F., additional, Zilli, T., additional, Khanfir, K., additional, Hemmatazad, H., additional, De Bari, B., additional, Klass, D., additional, Adnan, S., additional, Peulen, H., additional, Salinas Ramos, J., additional, Strijbos, M., additional, Popat, S., additional, Ost, P., additional, and Guckenberger, M., additional

Published
2023
Full Text
View/download PDF

13. Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

Author

Jereczek-Fossa, B, Marvaso, G, Zaffaroni, M, Gugliandolo, S, Zerini, D, Corso, F, Gandini, S, Alongi, F, Bossi, A, Cornford, P, De Bari, B, Fonteyne, V, Hoskin, P, Pieters, B, Tree, A, Arcangeli, S, Fuller, D, Franzese, C, Hannoun-Levi, J, Janoray, G, Kerkmeijer, L, Kwok, Y, Livi, L, Loi, M, Miralbell, R, Pasquier, D, Pinkawa, M, Scher, N, Scorsetti, M, Shelan, M, Toledano, A, van As, N, Vavassori, A, Zilli, T, Pepa, M, Ost, P, Jereczek-Fossa B. A., Marvaso G., Zaffaroni M., Gugliandolo S. G., Zerini D., Corso F., Gandini S., Alongi F., Bossi A., Cornford P., De Bari B., Fonteyne V., Hoskin P., Pieters B. R., Tree A. C., Arcangeli S., Fuller D. B., Franzese C., Hannoun-Levi J. -M., Janoray G., Kerkmeijer L., Kwok Y., Livi L., Loi M., Miralbell R., Pasquier D., Pinkawa M., Scher N., Scorsetti M., Shelan M., Toledano A., van As N., Vavassori A., Zilli T., Pepa M., Ost P., Jereczek-Fossa, B, Marvaso, G, Zaffaroni, M, Gugliandolo, S, Zerini, D, Corso, F, Gandini, S, Alongi, F, Bossi, A, Cornford, P, De Bari, B, Fonteyne, V, Hoskin, P, Pieters, B, Tree, A, Arcangeli, S, Fuller, D, Franzese, C, Hannoun-Levi, J, Janoray, G, Kerkmeijer, L, Kwok, Y, Livi, L, Loi, M, Miralbell, R, Pasquier, D, Pinkawa, M, Scher, N, Scorsetti, M, Shelan, M, Toledano, A, van As, N, Vavassori, A, Zilli, T, Pepa, M, Ost, P, Jereczek-Fossa B. A., Marvaso G., Zaffaroni M., Gugliandolo S. G., Zerini D., Corso F., Gandini S., Alongi F., Bossi A., Cornford P., De Bari B., Fonteyne V., Hoskin P., Pieters B. R., Tree A. C., Arcangeli S., Fuller D. B., Franzese C., Hannoun-Levi J. -M., Janoray G., Kerkmeijer L., Kwok Y., Livi L., Loi M., Miralbell R., Pasquier D., Pinkawa M., Scher N., Scorsetti M., Shelan M., Toledano A., van As N., Vavassori A., Zilli T., Pepa M., and Ost P.

Abstract

Background and purpose: Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body RT (SBRT) is emerging as a feasible and safe therapeutic option. However, no consensus or guidelines exist on this topic. The purpose of this ESTRO ACROP project is to investigate expert opinion on salvage SBRT for intraprostatic relapse after RT. Materials and Methods: A 40-item questionnaire on salvage SBRT was prepared by an internal committee and reviewed by a panel of leading radiation oncologists plus a urologist expert in prostate cancer. Following the procedure of a Delphi consensus, 3 rounds of questionnaires were sent to selected experts on prostate re-irradiation. Results: Among the 33 contacted experts, 18 (54.5%) agreed to participate. At the end of the final round, participants were able to find consensus on 14 out of 40 questions (35% overall) and major agreement on 13 questions (32.5% overall). Specifically, the consensus was reached regarding some selection criteria (no age limit, ECOG 0–1, satisfactory urinary flow), diagnostic procedures (exclusion of metastatic disease, SBRT target defined on the MRI) and therapeutic approach (no need for concomitant ADT, consideration of the first RT dose, validity of Phoenix criteria for salvage SBRT failure). Conclusion: While awaiting the results of ongoing studies, our ESTRO ACROP Delphi consensus may serve as a practical guidance for salvage SBRT. Future research should address the existing disagreements on this promising approach.

Published
2021

14. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study

Author

Nicosia, L, Franceschini, D, Perrone, F, Casamassima, F, Gerardi, M, Perna, M, Scotti, V, Fodor, A, Mazzola, R, Rigo, M, Iurato, A, Pasqualetti, F, Chiesa, S, Niespolo, R, Bruni, A, Frassinelli, L, Borghetti, P, Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Valdagni, R, Fazio, I, Corti, L, Vavassori, L, Maranzano, E, Magrini, S, Lohr, F, Arcangeli, S, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, Alongi, F, Nicosia L., Franceschini D., Perrone F., Casamassima F., Gerardi M. A., Perna M., Scotti V., Fodor A., Mazzola R., Rigo M., Iurato A., Pasqualetti F., Chiesa S., Niespolo R. M., Bruni A., Frassinelli L., Borghetti P., Marzo A. D., Ravasio A., De Bari B., Sepulcri M., Aiello D., Mortellaro G., Sangalli C., Franceschini M., Montesi G., Aquilanti F. M., Valdagni R., Fazio I., Corti L., Vavassori L., Maranzano E., Magrini S., Lohr F., Arcangeli S., Valentini V., Paiar F., Ramella S., Di Muzio N. G., Livi L., Jereczek-Fossa B. A., Osti M. F., Scorsetti M., Alongi F., Nicosia, L, Franceschini, D, Perrone, F, Casamassima, F, Gerardi, M, Perna, M, Scotti, V, Fodor, A, Mazzola, R, Rigo, M, Iurato, A, Pasqualetti, F, Chiesa, S, Niespolo, R, Bruni, A, Frassinelli, L, Borghetti, P, Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Valdagni, R, Fazio, I, Corti, L, Vavassori, L, Maranzano, E, Magrini, S, Lohr, F, Arcangeli, S, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, Alongi, F, Nicosia L., Franceschini D., Perrone F., Casamassima F., Gerardi M. A., Perna M., Scotti V., Fodor A., Mazzola R., Rigo M., Iurato A., Pasqualetti F., Chiesa S., Niespolo R. M., Bruni A., Frassinelli L., Borghetti P., Marzo A. D., Ravasio A., De Bari B., Sepulcri M., Aiello D., Mortellaro G., Sangalli C., Franceschini M., Montesi G., Aquilanti F. M., Valdagni R., Fazio I., Corti L., Vavassori L., Maranzano E., Magrini S., Lohr F., Arcangeli S., Valentini V., Paiar F., Ramella S., Di Muzio N. G., Livi L., Jereczek-Fossa B. A., Osti M. F., Scorsetti M., and Alongi F.

Abstract

PURPOSE/OBJECTIVE(S): stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases still remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate how lung SBRT can impact on the progression to the polymetastatic disease (PMD). MATERIALS/METHODS: the study involved 22 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1023 lung metastases treated with SBRT in 622 patients were reported. The median BED was 105 Gy10. Lesion diameter GTV, PTV volume, dose, fractionations, and site of primary tumor were evaluated as potential predictive marker for SBRT response for the primary end-point local progression-free survival (LPFS). EGFR, KRAS, NRAS, BRAF, and MSI were also evaluated. Secondary end-point was the time to the polymetastatic conversion (ttPMC). RESULTS: the median follow-up was 26 months (range 3-117 months). The median lesion diameter was 13 mm (range 4-58 mm). The 2- and 3-year LPFS were 75.6% and 71%, respectively. At the univariate analysis, BED ≥125Gy10 was associated with improved LPFS (2-year: 94.1% versus 72.6%; P = < 0.0001), single fraction SBRT correlated with better LPFS in the overall population (2-year: 80.6% versus 73.7%; P = 0.03), but no significant difference was observed when considering the population treated with BED > 100 Gy10. Lesion diameter ≤19 mm correlated with improved LPFS (2-year 80% versus 60%; P = < 0.0001). The median ttPMC was 26 months, and the 2-year ttPMC was 54.5%. The median PFS was 11.3 months. After SABR, 36% patients had polymetastatic relapse, 39.5% patients had an oligometastatic relapse, and 24.5% patients had no further relapse. CONCLUSION: the present is the largest series of lung colorectal metastases treated with SABR. The results support the use of SBRT in lung oligometastatic colorectal canc

Published
2021

16. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinos E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A, Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, Ja, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A

Subjects
Treatment, Consensus, Follow-up, education, Bladder cancer, Diagnosis, Consensu, Delphi, Diagnosi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.Setting: Online Delphi survey and consensus conference.Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and

Published
2020

21. OC-0602 A pREDictive model of polymetastatic disease on oligometastatic colorectal cancer: the RED LaIT-SABR

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone Congedi, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Rigo, M., additional, Mazzola, R., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Iurato, A., additional, Pasqualetti, F., additional, Gadducci, G., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Alicino, G., additional, Frassinelli, L., additional, Borghetti, P., additional, Di Marzo, A., additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Lunardi, G., additional, Valdagni, R., additional, Fazio, I., additional, Corti, L., additional, Vavassori, V., additional, Maranzano, E., additional, Magrini, S.M., additional, Arcangeli, S., additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek- Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

25. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone-Congedi, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Rigo, M., additional, Mazzola, R., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Iurato, A., additional, Pasqualetti, F., additional, Gadducci, G., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Alicino, G., additional, Frassinelli, L., additional, Borghetti, P., additional, Di Marzo, A., additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Lunardi, G., additional, Valdagni, R., additional, Fazio, I., additional, Scarzello, Giovanni, additional, Corti, L., additional, Vavassori, V., additional, Maranzano, E., additional, Magrini, S.M., additional, Arcangeli, S., additional, Gambacorta, Maria Antonietta, additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek-Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

28. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Mazzola, R., additional, Rigo, M., additional, Iurato, A., additional, Pasqualetti, F., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Frassinelli, L., additional, Borghetti, P., additional, Marzo, A. Di, additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Valdagni, R., additional, Fazio, I., additional, Corti, L., additional, Vavassori, L., additional, Maranzano, E., additional, Magrini, S., additional, Lohr, F., additional, Arcangeli, S., additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek-Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

29. Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series

Author

A. Saidi, Mahmut Ozsahin, Jean Bourhis, D. Hahnloser, M. Montemurro, Maira Biggiogero, Alessandra Franzetti-Pellanda, Michele Zeverino, and De Bari B

Subjects
Adult, Male, 0301 basic medicine, Antimetabolites, Antineoplastic, Cancer Research, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Original Article – Clinical Oncology, Image-guided radiotherapy, Tomotherapy, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic/therapeutic use, Capecitabine/therapeutic use, Chemoradiotherapy, Adjuvant, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Radiotherapy, Image-Guided, Rectal Neoplasms/diagnostic imaging, Rectal Neoplasms/drug therapy, Rectal Neoplasms/radiotherapy, Rectal Neoplasms/therapy, Tomography, X-Ray Computed, Whole Body Imaging, Helical tomotherapy, Neoadjuvant chemoradiotherapy, Rectal cancer, Toxicity, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, medicine, Chemotherapy, Rectal Neoplasms, business.industry, Correction, General Medicine, medicine.disease, Confidence interval, Radiation therapy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Radiology, business, medicine.drug
Abstract

Purpose Helical tomotherapy (HT) has been recently introduced in the neoadjuvant treatment of locally advanced rectal cancer. Aim of this study is to report the toxicity and local control rates of a large series of locally advanced rectal cancer patients treated with neoadjuvant chemotherapy and HT under daily image guidance followed by surgery. Methods Data from 117 locally advanced rectal cancer patients treated at two Swiss Radiotherapy departments were collected and analyzed. Radiotherapy consisted of 45 Gy (1.8 Gy/fraction, 5 fractions/week delivered in 5 weeks) to the regional pelvic lymph nodes. Seventy patients also received a simultaneous integrated boost (SIB) up to 50 Gy to the tumor and involved nodes (2 Gy/fraction, 5 fractions/week delivered in 5 weeks). Chemotherapy consisted of capecitabine 825 mg/m2, twice daily, during the irradiation days. After a median interval of 59 days [95% confidence interval (CI) 53–65 days), all patients underwent surgery. Results Median follow-up was 45 months (range 4–90 months). The overall rate of acute grade 2–4 toxicity was 18.8% (n = 22). Four patients (3.4%) presented a grade 3 dermatitis (n = 1) or diarrhea (n = 3), and 1 (0.8%) demonstrated grade 4 rectal toxicity. No patients presented with grade ≥ 3 hematologic toxicity. Six patients (5.1%) had late grade 3 gastrointestinal toxicity. The 4-year local control rate was 88.4% (95% CI 87.5–88.5%). Conclusions Neoadjuvant chemoradiotherapy delivered with HT under daily image guidance is well tolerated and shows a high 4-year local control rates.

Published
2019

32. PH-0112 Multicenter large retrospectIve database on SBRT for colorectal lung metastases: the LaIT-SABR study

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone Congedi, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Mazzola, R., additional, Rigo, M., additional, Iurato, A., additional, Pasqualetti, F., additional, Gadducci, G., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Frassinelli, L., additional, Borghetti, P., additional, Di Marzo, A., additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Valdagni, R., additional, Fazio, I., additional, Corti, L., additional, Vavassori, L., additional, Maranzano, E., additional, Magrini, S.M., additional, Lohr, F., additional, Arcangeli, S., additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek-Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

38. ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies

Author

Valentini, Vincenzo, Cellini, Francesco, Riddell, A., Brunner, T. B., Roeder, F., Giuliante, Felice, Alfieri, Sergio, Manfredi, Riccardo, Ardito, Francesco, Fiorillo, Claudio, Porziella, Venanzio, Morganti, Alessio Giuseppe, Haustermans, K., Margaritora, Stefano, De Bari, B., Matzinger, O., Gkika, E., Belka, C., Allum, W., Verheij, M., Valentini V. (ORCID:0000-0003-4637-6487), Cellini F. (ORCID:0000-0002-2145-2300), Giuliante F. (ORCID:0000-0001-9517-8220), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Ardito F. (ORCID:0000-0003-1596-2862), Fiorillo C. (ORCID:0000-0001-7681-3567), Porziella V. (ORCID:0000-0001-6000-3172), Morganti A. G., Margaritora S. (ORCID:0000-0002-9796-760X), Valentini, Vincenzo, Cellini, Francesco, Riddell, A., Brunner, T. B., Roeder, F., Giuliante, Felice, Alfieri, Sergio, Manfredi, Riccardo, Ardito, Francesco, Fiorillo, Claudio, Porziella, Venanzio, Morganti, Alessio Giuseppe, Haustermans, K., Margaritora, Stefano, De Bari, B., Matzinger, O., Gkika, E., Belka, C., Allum, W., Verheij, M., Valentini V. (ORCID:0000-0003-4637-6487), Cellini F. (ORCID:0000-0002-2145-2300), Giuliante F. (ORCID:0000-0001-9517-8220), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Ardito F. (ORCID:0000-0003-1596-2862), Fiorillo C. (ORCID:0000-0001-7681-3567), Porziella V. (ORCID:0000-0001-6000-3172), Morganti A. G., and Margaritora S. (ORCID:0000-0002-9796-760X)

Abstract

The European SocieTy for Radiation and Oncology -Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) endorsed a project to provide guidelines (GL) for the identification and delineation of clinically negative lymph-nodal stations (LNs) involved in upper gastrointestinal clinical scenarios. The presented GL is focused on preoperative (or definitive) setting. The project aim is to improve the consistency of clinical target volume (CTV) delineation by providing: a description of the anatomical boundaries of the LNs; a radiological computed tomography-based atlas depicting the LNs areas; a free, web-based, interactive example case for independent training of radiation oncologists on LNs delineation according to the presented GL, by both qualitative and quantitative analysis (through the FALCON EduCase platform). This project was carried out with the intention to facilitate and improve uniformity of future upper gastrointestinal guidelines on nodal CTV delineation. We report methodology and results from the collaboration of a working group panel selected by the ESTRO-ACROP.

Published
2021

42. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

Author

Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.

Abstract

The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology

Published
2020

43. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Subjects
Consensus, Follow-up, education, Bladder cancer, Diagnosis, Treatment, Delphi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

44. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, JA, Babjuk, M, Bellmunt, J, Bruins, HM, De Reijke, TM, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmueller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Mueller, A-C, Mueller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, M, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, RJ, Smits, A, Stenzl, A, Thalmann, GN, Tombal, B, Turkbey, B, Lauridsen, SV, Valdagni, R, Van der Heijden, AG, Van Poppel, H, Vartolomei, MD, Veskimae, E, Vilaseca, A, Rivera, FAV, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Horwich, A, Witjes, JA, Babjuk, M, Bellmunt, J, Bruins, HM, De Reijke, TM, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmueller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Mueller, A-C, Mueller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, M, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, RJ, Smits, A, Stenzl, A, Thalmann, GN, Tombal, B, Turkbey, B, Lauridsen, SV, Valdagni, R, Van der Heijden, AG, Van Poppel, H, Vartolomei, MD, Veskimae, E, Vilaseca, A, Rivera, FAV, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A

Abstract

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus stateme

Published
2020

45. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

Author

Mauri, D., Kamposioras, K., Tolia, M., Alongi, F., Tzachanis, D., Petricevic, B., Chilingirova, N., Mihaylova, I., Tsakiridis, T., Salembier, C., Papadimitriou, K., De Mello, R. A., Amaral, G. A., Neves, N. M., Dias, R., Yi, J., Dedic Plavetic, N., Antunac, K., Kountourakis, P., Kopecky, J., Christopoulos, C., Pavese, I., Corradini, S., Zarkavelis, G., Papadaki, A., Gkantaifi, A., Theodorelos, V., Capizzello, A., Lovey, J., Cellini, Francesco, Dambrosio, M., Takeuchi, D., Saraireh, H. H., Rotterud, R., Chojnacka, M., Papachristos, A., Djan, I., Popovic, L., Grasic Kuhar, C., Strojan, P., Hindi, N., Valachis, A., Ahs, M., De Bari, B., Santa Cruz, O., Hameed, H., Takeuchi, E., Apostolidis, K., Cardone, A., Gono, P., Filis, P., Cellini F. (ORCID:0000-0002-2145-2300), Mauri, D., Kamposioras, K., Tolia, M., Alongi, F., Tzachanis, D., Petricevic, B., Chilingirova, N., Mihaylova, I., Tsakiridis, T., Salembier, C., Papadimitriou, K., De Mello, R. A., Amaral, G. A., Neves, N. M., Dias, R., Yi, J., Dedic Plavetic, N., Antunac, K., Kountourakis, P., Kopecky, J., Christopoulos, C., Pavese, I., Corradini, S., Zarkavelis, G., Papadaki, A., Gkantaifi, A., Theodorelos, V., Capizzello, A., Lovey, J., Cellini, Francesco, Dambrosio, M., Takeuchi, D., Saraireh, H. H., Rotterud, R., Chojnacka, M., Papachristos, A., Djan, I., Popovic, L., Grasic Kuhar, C., Strojan, P., Hindi, N., Valachis, A., Ahs, M., De Bari, B., Santa Cruz, O., Hameed, H., Takeuchi, E., Apostolidis, K., Cardone, A., Gono, P., Filis, P., and Cellini F. (ORCID:0000-0002-2145-2300)

Abstract

N/A

Published
2020

46. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper.

Author

Valentini, V, Marijnen, C, Beets, G, Bujko, K, De Bari, B, Cervantes, A, Chiloiro, G, Coco, C, Gambacorta, Ma, Glynne-Jones, R, Haustermans, K, Meldolesi, E, Peters, F, Rödel, C, Rutten, H, van de Velde, C, Aristei, C., Valentini V (ORCID:0000-0003-4637-6487), Chiloiro G, Coco C (ORCID:0000-0002-4713-7093), Gambacorta MA (ORCID:0000-0001-5455-8737), Meldolesi E, Valentini, V, Marijnen, C, Beets, G, Bujko, K, De Bari, B, Cervantes, A, Chiloiro, G, Coco, C, Gambacorta, Ma, Glynne-Jones, R, Haustermans, K, Meldolesi, E, Peters, F, Rödel, C, Rutten, H, van de Velde, C, Aristei, C., Valentini V (ORCID:0000-0003-4637-6487), Chiloiro G, Coco C (ORCID:0000-0002-4713-7093), Gambacorta MA (ORCID:0000-0001-5455-8737), and Meldolesi E

Abstract

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The controversial clinical issues that had been identified within cT2-cT3-cT4 needed further investigation. The discussions focused on the role of (1) neoadjuvant therapy and organ preservation on cT2-3a low-middle rectal cancer; (2) neoadjuvant therapy in cT3 low rectal cancer without high risk features; (3) total neoadjuvant therapy, radiotherapy boost and the best chemo-radiotherapy schedule in T4 tumors. A description of each area of investigation and trial proposals are reported. CONCLUSION: The meeting successfully identified 'grey zones' and, in the light of new evidence, proposed clinical trials for treatment of early, intermediate and advanced stage rectal cancer.

Published
2020

47. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

Author

Valentini, V., Marijnen, C., Beets, G., Bujko, K., De Bari, B., Cervantes, A., Chiloiro, G., Coco, C., Gambacorta, M. A., Glynne-Jones, R., Haustermans, K., Meldolesi, E., Peters, F., Rodel, C., Rutten, H., van de Velde, C., Aristei, C., Valentini V. (ORCID:0000-0003-4637-6487), Chiloiro G., Coco C. (ORCID:0000-0002-4713-7093), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Meldolesi E., Valentini, V., Marijnen, C., Beets, G., Bujko, K., De Bari, B., Cervantes, A., Chiloiro, G., Coco, C., Gambacorta, M. A., Glynne-Jones, R., Haustermans, K., Meldolesi, E., Peters, F., Rodel, C., Rutten, H., van de Velde, C., Aristei, C., Valentini V. (ORCID:0000-0003-4637-6487), Chiloiro G., Coco C. (ORCID:0000-0002-4713-7093), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Meldolesi E.

Abstract

Background and purposes: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)’s discussions (‘grey zones’) and propose next generation studies which may provide answers to them. Materials and methods: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a ‘grey zone’. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. Results: The controversial clinical issues that had been identified within cT2–cT3–cT4 needed further investigation. The discussions focused on the role of (1) neoadjuvant therapy and organ preservation on cT2-3a low-middle rectal cancer; (2) neoadjuvant therapy in cT3 low rectal cancer without high risk features; (3) total neoadjuvant therapy, radiotherapy boost and the best chemo-radiotherapy schedule in T4 tumors. A description of each area of investigation and trial proposals are reported. Conclusion: The meeting successfully identified ‘grey zones’ and, in the light of new evidence, proposed clinical trials for treatment of early, intermediate and advanced stage rectal cancer.

Published
2020

48. A Multicenter Large Retrospective Database On The Personalization Of Stereotactic Ablative Radiotherapy For Lung Metastases From Colon-rectal Cancer: Early Results From The LaIT-SABR Study

Author

Nicosia, L., primary, Rigo, M., additional, Franceschini, D., additional, Scorsetti, M., additional, Perrone, F., additional, Osti, M.F., additional, Ravasio, A., additional, Vavassori, V., additional, Borghetti, P., additional, Magrini, S., additional, Bruni, A., additional, Frassinelli, L., additional, Lohr, F., additional, Di Marzo, A., additional, Maranzano, E., additional, Slimani, S., additional, De Bari, B., additional, Mazzola, R., additional, and Alongi, F., additional

Published
2020
Full Text
View/download PDF

49. OC-0694: An ESTRO-ACROP Delphi consensus on salvage SBRT for intraprostatic relapse after PCa radiotherapy

Author

Jereczek-Fossa, B.A., primary, Marvaso, G., additional, Pepa, M., additional, Gugliandolo, S.G., additional, Zerini, D., additional, Gandini, S., additional, Vavassori, A., additional, De Bari, B., additional, Alongi, F., additional, Fonteyne, V., additional, Pieters, B., additional, Hoskin, P., additional, Tree, A., additional, Bossi, A., additional, Cornford, P., additional, Toledano, A., additional, Hannoun-Levi, J., additional, Miralbell, R., additional, Fuller, D., additional, Scorsetti, M., additional, Arcangeli, S., additional, Livi, L., additional, Janoray, G., additional, Pasquier, D., additional, and Ost, P., additional

Published
2020
Full Text
View/download PDF

50. PO-0956: Neuroendocrine Tumors of the Breast: an international series of the Rare Cancer Network

Author

Grellier-Adedjouma, N., primary, Paix, A., additional, Franco, P., additional, Kirova, Y.M., additional, De Bari, B., additional, Pasquier, D., additional, Meijer, H., additional, Oksüz, D.C., additional, Peignaux-Casasnovas, K., additional, Huguet, F., additional, De Caluwé, A., additional, Khanfir, K., additional, Vargas, A., additional, Thariat, J., additional, Vargo, J.A., additional, Ozsahin, E.M., additional, and Belkacemi, Y., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results